English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/81677
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Targeting Mannose Binding Lectin Confers Long Lasting Protection with a Surprisingly Wide Therapeutic Window in Cerebral Ischemia

AuthorsOrsini, Franca; Villa, Pia; Parrella, Sara; Zangari, Rosalia; Zanier, Elisa R.; Gesuete, Raffaella; Stravalaci, Matteo; Fumagalli, Stefano; Ottria, Roberta; Reina, José J. ; Paladini, Alessandra; Micotti, Edoardo; Ribeiro-Viana, Renato ; Rojo, Javier ; Pavlov, Vasile I.; Stahl, Gregory L.; Bernardi, Anna; Gobbi, Marco; Simoni, Maria-Grazia de
Issue Date2012
PublisherLippincott Williams & Wilkins
CitationCirculation 126: 1484- 1494 (2012)
AbstractAbstract Background—The involvement of the complement system in brain injury has been scarcely investigated. Here, we document the pivotal role of mannose-binding lectin (MBL), one of the recognition molecules of the lectin complement pathway, in brain ischemic injury. Methods and Results—Focal cerebral ischemia was induced in mice (by permanent or transient middle cerebral artery occlusion) and rats (by 3-vessel occlusion). We first observed that MBL is deposited on ischemic vessels up to 48 hours after injury and that functional MBL/MBL-associated serine protease 2 complexes are increased. Next, we demonstrated that (1) MBL−/− mice are protected from both transient and permanent ischemic injury; (2) Polyman2, the newly synthesized mannosylated molecule selected for its binding to MBL, improves neurological deficits and infarct volume when given up to 24 hours after ischemia in mice; (3) anti-MBL-A antibody improves neurological deficits and infarct volume when given up to 18 hours after ischemia, as assessed after 28 days in rats. Conclusions—Our data show an important role for MBL in the pathogenesis of brain ischemic injury and provide a strong support to the concept that MBL inhibition may be a relevant therapeutic target in humans, one with a wide therapeutic window of application.
Identifiersdoi: 10.1161/​CIRCULATIONAHA.112.103051
issn: 0009-7322
Appears in Collections:(IIQ) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.